Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope your wrong there are no .02 warrants.
On January 7, 2016, the Company entered into Stock and Warrant Purchase Agreements with two investors and closed a private placement to them. Pursuant to the Stock and Warrant Purchase Agreements, the Company sold to the investors, in equal amounts, an aggregate of 17,000,000 shares of its unregistered common stock, and also sold to the investors, in equal amounts, unregistered warrants to purchase an additional total of 17,000,000 shares of its unregistered common stock, for $1,020,000 in aggregate gross proceeds. The terms of the Stock and Warrant Purchase Agreements for these warrants state the exercise price is $0.12 per share and the expiration date of these warrants is January 7, 2021. Using the Black Scholes warrant pricing model, the Company determined the aggregate value of these warrants to be approximately $967,000. These warrants have a cashless exercise feature.
I have and the only warrants i see are at .12
What funding company are you talking about? I you talking about the warrants that the SPYR people have from the last private placement?
The company "HAD" the ability to raise capital for clinical trials and more but the CEO did not have the foresight to do so while the market cap was well above 75 million.
$22,000,000 in Compensation expense since 2014 almost as much as the current market cap.
Back to 2011 levels. Good job Kenny esq.
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers. From 10/1/15
I thought the MM's were still manipulating the price??
I keep hearing the clinical trial in (correction) q4 2016 drumbeat but given the time lines for pre-ind then ind then prep time to start even if everything went perfect i don't see it and its just another either dishonest statement from KW or its a total lack of understanding the clinical process.
Request for pre-ind:
FDA responds within 7 days and sets a date no later then 60 days from request time.
After pre-ind meeting:
FDA sends meeting minutes with points discussed and any issues they need addressed within 30 days from meeting.
IND sent:
If no issues trial may begin after 30 days.
So if everything started today it would be 120 days if EVERYTHING went perfect. No issues No questions and a trial site all trained just waiting to treat the first patient.
I keep hearing the clinical trial in 2017 drumbeat but given the time lines for pre-ind then ind then prep time to start even if everything went perfect i don't see it and its just another either dishonest statement from KW or its a total lack of understanding the clinical process.
Request for pre-ind:
FDA responds within 7 days and sets a date no later then 60 days from request time.
After pre-ind meeting:
FDA sends meeting minutes with points discussed and any issues they need addressed within 30 days from meeting.
IND sent:
If no issues trial may begin after 30 days.
So if everything started today it would be 120 days if EVERYTHING went perfect. No issues No questions and a trial site all trained just waiting to treat the first patient.
You can't give a better example of not protecting shareholder value then that chart.
Its hard to live off a measly 165k in salary and bonus. Kenny esq has "only" spent $22,000,000 in Compensation expense since he took over.
Wouldn't it be nice if the $7,000,000 in shares given to Patricia Gruden and Timothy Matula when they left the company were instead sold and the cash still in the bank for clinical trials. Strange also that these two people sold those shares. Can't think of two people associated with this company that deserved $0 more then these two. Oh my bad i forgot about Dr. Ryan.
The disclaimer at the end of this video at the 6:29 minute mark states that Small Cap Nation is to be compensated up to $10,000 from PMCB.
Wouldn't it be nice to have that $2,000,000 back that was spent on the
"Exclusive Worldwide License to Develop Treatments Combining Cell-in-a-Box and Cannabinoid-Based Meds"
All of the money spent on corporate videos and paid web interviews and paid press releases and paid email promotions and what did they deliver a .04 stock. Wouldn't it be nice to still have the hundreds of thousands of dollars still in the bank right now.
That's great but you can't spend non disclosure agreements. Companies sign them everyday i believe they are for not disclosing information. How about trying to sign a partnership for development agreement those are the only ones that matter here. eom ....
When a company has dwindling cash on hand and seemingly no ability to raise cash giving yourself a 30% raise does not sit well with investors which is why the PPS continues to decline. I think a CEO that was looking to protect shareholder value and success of their company would be more then satisfied making 150k and betting that their stock holdings would be their reward. Willing to wait 10 years? If this company does not get into a clinical trial and have great results there will be no company in 1 year.
Time to bring back Lincoln Park Capital for another round of pretend funding.
Then i guess that no one can prove that any of their expenses were paid for by selling shares. What a brilliant point LOL !!!!!
I believe the point is that every expense they pay is from sales of shares. Where else would the money come from?
Maybe you need to actually read my post. Did i say rich?
From where i am sitting it looks like a 68 year year old CEO and a 75 year old COO are making sure its not them that ends up with nothing "IF" this company doesn't make it.
A well funded bio company with a 500 million dollar market cap probably has less then a 5% chance of making it. If the word "IF" was ever warranted it is here.
You are correct and his pay is not just on paper he also gave himself a 30% raise in salary. And yes it is a big slap in the face to investors to be rewarding yourself for something you have yet to accomplish.
"WE" all don't understand where the money is coming from but "WE" all know that Kenny esq should have been raising money when the PPS was much more favorable and he was able to use the ATM. My question is who is going to give them money after seeing how they spend their money year after year.
I will believe it when i see it. No ATM available and 1.3 million left in cash. 500k just to file an Ind and at least that much in cost to set up a trial. And several million to conduct a trial.
The i don't care about the PPS is a foolish position as it directly affects their ability to raise needed funding.
samsung biologics is a supplier of biologics isn't that what Austrianova is for ?
Many companies have signed NDA's and as proof you post a link that is a year old that states the following:
For the time being, PharmaCyte is comfortably financed through a $50 million at-the-market facility. But with the prospect of large trials looming down the road, the company also is assessing the interest of big pharmas, and many have signed non-disclosure agreements.
So no big pharma has stepped up and now the $50 million is also not available so i guess that was a bad point raised by you.
From what i am seeing it has not attracted interest from anyone except a bunch of individual investors hoping to hit the lottery. You would think at this point if all of these top of their profession Doctors and scientists had this impeccable reputation i keep hearing some claim that some investor with money to burn would take a chance. Maybe Kenny esq should offer existing investors the opportunity to purchase half of a share for every share they own at .035 that way even if 20% took the offer they could raise 2.4 million $$ and those who claim to be accumulating shares or trying to help a company that is trying to cure cancer will actually be helping the company and not just buying shares from other people.
780,000,000 shares say 80,000,000 are owned by insiders that leaves 700,000,000. half of that is 350,000,000 20% buy in is 70,000,000 times .035 is $2,450,000 40% buy $4,900,000. Problem solved now i can enjoy my weekend.
That"s why you need a real Board of Directors to hold the CEO accountable to shareholders. KW has the power to do whatever he wants and there is nothing we can do about it.
It says that when you are the CEO and COTB and there is no real board of directors or shareholder voting you can enrich yourself as much as you want.
Believe me i remember Dr. Ryan and Pat Gruden. You should remember that it was Ryan that hired Crabtree and Gruden that hired KW. Those are not two people i don't want hiring a cleaning crew never mind a CEO and a COO. That's the biggest problem with OTC companies there is no independent BOD over site to answer to.
Point is you try and protect shareholder value by raising money in the most favorable conditions. They have had a ATM agreement for several years that could have been used a little every qtr to put some cash away for trials instead they waited for the market cap to dip to these levels and now they not only can't use that ATM they need to flood the market with 3-4 times as many shares. That is very poor planning and management. That's KW job! He is not a Doctor or a scientist i assume he was brought here to manage the company. That means looking at today, tomorrow and years down the road and i see none of that in him.
If they are selling for funding then good. But wow if KW waited until the price went this low to start selling shares to raise cash then he just doesn't know how to run a company. He should have been hitting the ATM button a year ago when he had that option to put money away.
If this is selling for funding then they still have about 100,000,000 share to sell at this level.
I guess in he alternate universe of the Kenny esq. fan club there is no problem here. Kenny gives a prerecorded CC and releases the horrible financials and the stock bleeds red. No problem. The company only needs to sell 100,000,000 shares at this level to fund the IND application and the first six months of a clinical trial. No problem. I am sure he is just busy busy at his desk going over all of the offers he has from institutional investors. Take a break Kenny and enjoy a long weekend its only been four years that this company has been promoting a clinical trial. No one expects you to work this hard for a lousy 195k paycheck and 3 million $ in stock. There is always Q1 2017 or 2018. I'm sure by the time you get around to trials you will have to change the design five or six more times anyway. Your shareholders will wait you super hero.
LOL!"They are searching for the best funding opportunity right now" Truth is they are searching for ANY funding opportunity right now.
Remember the famous Kenny esq shareholder update in July 2014. And I quote.
"Nuvilex has established credibility with accredited and institutional investors who have expressed a desire to fund Nuvilex’s expansion plans under reasonable terms"
You know the same one that stated.
"Nuvilex has completed the necessary preliminary steps to commence a Phase 2b clinical trial of its pancreatic cancer treatment that it expects to begin in Q1 2015"
Even though He knew this was impossible because Austrianova had no ability to produce the material required for any trial.
When will shareholders stop defending this complete lack of truthfulness.
This is what happens when you have a pretend shareholder CC and only answer questions that you are comfortable with. Then you release a 10K littered with negligent payouts to company employees that have accomplished nothing but issuing grossly misleading PR's and broken promises.
Yes there are plenty of facts out there. The most important one for shareholders of PMCB is that this clinical trial should not have taken close to four years to happen. There is no excuse for this. Not knowing that Australia does not have the patient population to conduct a trial there alone. Not being honest about Austrianova being unable to produce cells. Changing the trial design over and over. Not providing shareholders with funding details. It all points to Kenny esq not having the experience to run a bio tech company and his having complete control of this company with no independent board of directors.